small molecule

JELMYTO

MITOMYCIN

Loss of exclusivityJanuary 2031latest FDA-listed patent expiry

CompanyUroGen Pharma →View the full company profile on CliffBio

Drug detail

Brand name	JELMYTO
Active ingredient	MITOMYCIN
Strength	40MG/VIAL
Dosage form	POWDER
Route	PYELOCALYCEAL
Modality	Small molecule
FDA approval	April 2020
Marketing status	RX

Listed patents

Patent	Expires	Type
12268745	January 2031	use U-4172
9950069	January 2031	product
9040074	January 2031	product

Regulatory exclusivity

Code	Expires
ODE-289	April 2027

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from UroGen Pharma